Literature DB >> 24039234

Impact assessment of a decision rule for using antibiotics in pneumonia: a randomized trial.

Fernando A Torres1, Irma Pasarelli, Adrián Cutri, María F Ossorio, Fernando Ferrero.   

Abstract

BACKGROUND: Although more than half of the cases of pneumonia in children can be due to virus, most of them receive antibiotic treatment. A previously published clinical prediction rule bacterial pneumonia score (BPS) allows the identification of children with pneumonia who do not require antibiotics, but its impact has not been evaluated. We assessed whether the use of the BPS for the initial management of patients with pneumonia results in decreasing the use of antibiotics than under standard management of this condition without increasing patients' risks.
METHODS: This was a randomized, parallel-group, observer-blind, controlled clinical trial comparing the use of antibiotics in children aged 3-60 months treated for pneumonia in an outpatient setting, according to two methods of initial management. Patients were assigned randomly to management according to the BPS (antibiotic indication with a BPS ≥ 4 points) or routine management (antibiotic indication based on the institutional guidelines). We calculated the proportion of the use of antibiotics in each group and evaluated each patient's clinical outcome.
RESULTS: We included 120 patients (60 BPS and 60 controls) with a mean age of 24.2 ± 14.1 months. The use of antibiotics was significantly lower in the BPS group (46.6% vs. 86.6; OR 0.13; 95% CI: 0.05-0.35; P < 0.001). We observed an unfavorable outcome in 10 patients (8.3%), 5 in each group (P = 1.0; OR: 1.0 95% CI: 0.2-3.6).
CONCLUSION: The use of antibiotics was significantly lower in the group managed according to the BPS compared to the conventionally treated group, without increasing the rate of treatment failure.
© 2013 Wiley Periodicals, Inc.

Entities:  

Keywords:  acute respiratory infection; decision-support techniques; pneumonia

Mesh:

Substances:

Year:  2013        PMID: 24039234     DOI: 10.1002/ppul.22849

Source DB:  PubMed          Journal:  Pediatr Pulmonol        ISSN: 1099-0496


  6 in total

1.  Risk Model of Bacterial Coinfection in Children with Severe Viral Bronchiolitis.

Authors:  Michael C Spaeder; Refik Soyer
Journal:  J Pediatr Intensive Care       Date:  2016-06-29

2.  Ambulatory Antibiotic Stewardship through a Human Factors Engineering Approach: A Systematic Review.

Authors:  Sara C Keller; Pranita D Tamma; Sara E Cosgrove; Melissa A Miller; Heather Sateia; Julie Szymczak; Ayse P Gurses; Jeffrey A Linder
Journal:  J Am Board Fam Med       Date:  2018 May-Jun       Impact factor: 2.657

Review 3.  Systematic review of the effects of care provided with and without diagnostic clinical prediction rules.

Authors:  Sharon L Sanders; John Rathbone; Katy J L Bell; Paul P Glasziou; Jenny A Doust
Journal:  Diagn Progn Res       Date:  2017-04-26

4.  Evaluation of a clinical decision rule to guide antibiotic prescription in children with suspected lower respiratory tract infection in The Netherlands: A stepped-wedge cluster randomised trial.

Authors:  Josephine S van de Maat; Daphne Peeters; Daan Nieboer; Anne-Marie van Wermeskerken; Frank J Smit; Jeroen G Noordzij; Gerdien Tramper-Stranders; Gertjan J A Driessen; Charlie C Obihara; Jeanine Punt; Johan van der Lei; Suzanne Polinder; Henriette A Moll; Rianne Oostenbrink
Journal:  PLoS Med       Date:  2020-01-31       Impact factor: 11.069

Review 5.  Implementation and impact of pediatric antimicrobial stewardship programs: a systematic scoping review.

Authors:  D Donà; E Barbieri; M Daverio; R Lundin; C Giaquinto; T Zaoutis; M Sharland
Journal:  Antimicrob Resist Infect Control       Date:  2020-01-03       Impact factor: 4.887

6.  The Impact of Antimicrobial Stewardship in Children in Low- and Middle-income Countries: A Systematic Review.

Authors:  Yara-Natalie Abo; Bridget Freyne; Diana Kululanga; Penelope A Bryant
Journal:  Pediatr Infect Dis J       Date:  2022-03-01       Impact factor: 2.129

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.